Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof

A method for providing information for predicting therapeutic responsiveness of a cancer patient to a cancer immunotherapy, comprising:

• measuring an expression level of mRNA or protein of one or more genes selected from the group consisting of OPN, POSTN, and IGFBP-3 in a biological sample obtained from the cancer patient;
• and
• evaluating the patient's therapeutic responsiveness to the cancer immunotherapy, based on the measured expression level of mRNA or protein.

A method for treating cancer based on therapeutic responsiveness of a cancer patient to a cancer immunotherapy, comprising:

• (i) administering the cancer immunotherapy to the cancer patient;
• and
• (ii) measuring an expression level of mRNA or protein of one or more genes selected from the group consisting of OPN, POSTN, and IGFBP-3 in a biological sample obtained from the cancer patient, before, after, or both before and after administration of the cancer immunotherapy.